Aslan Pharmaceuticals Limited (ASLN) Return on Equity ROE from the fourth quarter 2023 to fourth quarter 2022 and annually, average high and low, overall ranking from Dec 31 2023 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aslan Pharmaceuticals Limited  (NASDAQ: ASLN)

Aslan Pharmaceuticals Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Aslan Pharmaceuticals Limited in the fourth quarter 2023?
Due to the lack of equity, it was not possible to calculate Aslan Pharmaceuticals Limited's return on equity (ROE) in its fourth quarter 2023

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2023)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Equity Change - - -80.5 % - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -44 -51 -51 -51 -51
Return On Equity (TTM) - - -2094.18 % -569.14 % -355.81 %
ASLN's Total Ranking # # # # #
Equity (TTM) in Millions -13 -13 6 -13 8
Seq. Equity Change - - - - 0 %
Seq. Net Income Change - - - - -

Back to ASLN Management Effectiveness >> ASLN's 5 Years Annual ROE >> Compare ASLN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





ASLN Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions -13 8 57 -10 -1
Y / Y Equity Change - -85.4 % - - -
Net Income in Millions -44 -51 -32 -17 -47
Y / Y Net Income Change - - - - -
Return On Equity - -614.24 % -55.13 % - -

Back to ASLN Management Effectiveness >> ASLN's 5 Years Annual ROE >> Compare ASLN ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ASLN's' Return on Equity at Yahoo Finance
ASLN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ASLN's Competitors
Subscribers only: Roe for Aslan Pharmaceuticals Limited's Suppliers
Subscribers only: Return On Equity for ASLN's Customers




Companies with similar Return On Equity at Dec 31 2023, within Healthcare Sector ROE
Redhill Biopharma Ltd   1,155.92 %
Hca Healthcare Inc   1,154.69 %
Ir med Inc   370.14 %
Mimedx Group Inc   237.80 %
Halozyme Therapeutics Inc   204.84 %
Glucotrack Inc   171.97 %
Roivant Sciences Ltd   160.44 %
Ladrx Corporation  152.84 %
Biomx Inc  140.47 %
Icecure Medical Ltd  120.46 %
Scynexis Inc   117.56 %
Viskase Holdings inc   114.23 %

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.